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Diabetic nephropathy shows a higher incidence in male
subjects, which may in part be owing to genetic factors. The
angiotensin II type 2 receptor (AT2), present in the renal
glomerulus, may oppose the deleterious effects of the type I
receptor (AT1) through vasodilatation and growth inhibition.
We determined whether the functional intronic G1675A or
A1818T polymorphism of the X-chromosomal AT2 gene is
associated with blood pressure levels or with kidney function.
We genotyped 996 (538 female/458 male subjects) Finnish
patients with type I diabetes from the FinnDiane-study in a
cross-sectional study. DNA samples were amplified using
standard polymerase chain reaction protocol and the
genotypes were determined by the minisequencing method.
Male patients with the AA haplotype had a lower glomerular
filtration rate (83732 vs 94734 ml min1 1.73 m2,
P¼ 0.008) and a higher pulse pressure (PP) (62718 vs
57715 mm Hg, P¼ 0.002; Po0.05 after adjustment for age)
than did those with the GT haplotype. No differences
between the genotypes or haplotypes and these variables
were evident in females. In males, the G1675A was also an
independent variable in a linear regression analysis with PP
(r2¼ 0.16, coefficient¼ 3.64, s.e.m.¼ 1.38, Po0.01) as the
dependent variable. These data suggest a gender-specific
association between the AT2 gene and kidney function and
premature aging of the arterial tree in patients with type I
diabetes.
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Gender is an important risk factor for the development and
progression of diabetic nephropathy (DN). In general, males
with type I diabetes have both a higher incidence of DN1 and
a faster progression of kidney disease.2 The renin–angiotensin–
aldosterone system, a key mediator of diabetic kidney disease,
is partly under genetic control. A number of studies have
suggested that the angiotensin-converting enzyme gene I/D
polymorphism and, more recently, polymorphisms in the
angiotensin II type I receptor (AT1) are associated with more
aggressive microvascular disease. Recently, an important role
has been proposed for the renal angiotensin II type 2 receptor
(AT2).3 AT2 can oppose the deleterious effects of the AT1
through vasodilatation and growth inhibition,4 although this
has also been questioned by recent data that have suggested
that AT1 and AT2 may also share some signaling pathways.5
Furthermore, in adult rat kidney, AT2 is clearly detectable in
glomerular epithelial cells, cortical tubules, and interstitial
cells.6
In a few studies of subjects without diabetes, polymor-
phisms in the AT2 gene have been associated with hyperten-
sion,7 coronary ischemia,7 and left ventricular mass.8,9
However, unlike angiotensin-converting enzyme or AT1,
activity of AT2 may be gender dependent, as the AT2 gene is
located on the X chromosome. We hypothesize that
polymorphisms in the AT2 gene may be involved in
gender-dependent differences in blood pressure levels or
kidney function in patients with type I diabetes.
RESULTS
This study investigated G1675A, a functional polymorphism
in intron 1, and A1818T in intron 2 of the AT2 gene. The
minor allele frequencies were 0.45 and 0.28 in females and
0.46 and 0.27 in males for the G1675A and A1818T
polymorphism, respectively. The genotypes were in Hard-
y–Weinberg equilibrium in females for both polymorphisms
but could not be assessed in males. Linkage disequilibrium
analyses resulted in D0 ¼ 0.98 and r2¼ 0.31 in males and
D0 ¼ 0.97 and r2¼ 0.30 in females. The haplotypes were
distributed as GA (n¼ 250, 27%), GT (n¼ 251, 27%),
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AA (n¼ 412, 45%), and AT (n¼ 3, 0%) in 458 females and
GA (n¼ 146, 27%), GT (n¼ 142, 26%), AA (n¼ 247, 46%),
and AT (n¼ 1, 0%) in 536 males for the G1675A and A1818T
polymorphism, respectively.
The G allele of the G1675A, the T allele of the A1818T, and
the GT haplotype were more common in male patients with
normal glomerular filtration rate (GFR) according to the
Cockcroft–Gault formula (490 ml min1 1.73 m2) than in
those with impaired renal function (Table 1). The G allele of
the G1675A and the T allele of the A1818T were also
associated with a higher absolute GFR value after excluding
patients with end-stage renal disease and with a lower pulse
pressure (PP) and higher estimated glucose disposal rate
(Table 2). However, none of these associations appeared in
females. In addition, no association existed between AT2
genotype and albumin excretion rate in either males or
females (data not shown).
As the G allele of the G1675A and the T allele of the
A1818T appeared to be protective, when the haplotypes were
analyzed as AA against GT, males with the GT haplotype
showed similarly a higher GFR, a lower PP, and a higher
estimated glucose disposal rate than did those with the AA
haplotype (Table 3). This difference remained significant
after adjustment for age (Tables 2 and 3). Furthermore, the
G1675A was independently associated with PP (r2¼ 0.16,
coefficient¼ 3.64, s.e.¼ 1.38, Po0.01) after adjusting for
glycosylated hemoglobin, low-density lipoprotein cholesterol,
body mass index, and antihypertensive medication. Again, no
association appeared in females.
Despite an association among haplotypes of the AT2 gene,
renal function, and blood pressure in men, after adjustment
for age, no differences existed in the genotypes or in the
haplotypes of the AT2 gene as to prevalence of retinopathy or
diagnosed coronary heart disease. Nor were any differences
evident in time to onset of DN or end-stage renal disease for
either genotype or haplotype in either gender (data not
shown).
DISCUSSION
DN is more common and more severe in men.1,2 This is
apparently the first study showing a gender-specific associa-
tion between a gene haplotype/genotype and renal function.
Table 2 | Clinical characteristics according to AT2 polymorphisms in male patientsa
G1675A A1818T
Variable G A P A T P
n (%) 288 (53.7) 244 (46.3) — 395 (73.4) 143 (26.6) —
Age (years) 40.779.7 42.7710.3 0.024 42.0710.0 40.379.9 NS
Duration of diabetes (years) 27.678.6 28.678.7 NS 28.478.8 26.978.2 NS
HbA1c (%) 8.671.4 8.771.4 NS 8.671.4 8.671.4 NS
eGDR (mg kg1 min1) 5.1272.26 4.5172.20 0.003b 4.7072.24 5.2272.25 0.024c
SBP (mm Hg) 141719 145720 0.019c 143720 142717 NS
DBP (mm Hg) 84710 83710 NS 83710 85711 0.050c
PP (mm Hg) 57717 62718 o0.001b 61718 57715 0.028c
Albumin excretion rate (mg 24 h1)d 67 (2–7565) 136 (1–5589) NS 847 (1–5589) 68 (4–7586) NS
GFR (ml min1 1.73 m2)d 90.4732.4 83.4732.1 0.027e 85.0732.0 93.7732.8 0.016e
Diagnosed coronary heart disease 22 (8) 34 (14) 0.021c 48 (13) 9 (7) 0.048c
Retinal laser treatment 194 (68) 164 (67) NS 268 (69) 92 (65) NS
AT2, angiotensin II type 2 receptor; DBP, diastolic blood pressure; eGDR, estimated glucose disposal rate; GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin; NS,
not significant; PP, pulse pressure; SBP, systolic blood pressure.
Data are mean7s.d., median (range) or n (%).
aData are genotypes and allele frequencies simultaneously owing to X-chromosomal location.
bPo0.05 when adjusted for age.
cP=NS when adjusted for age.
dPatients with end-stage renal disease excluded.
eP=NS (G1675A) and P=0.005 (A1818T) when adjusted for duration of diabetes, use of angiotensin-converting enzyme inhibitors, and urinary albumin excretion rate.
Table 1 | Allele frequencies and haplotypes by GFR in all
patients
GFR490 60pGFRp90 GFRo60 P a
G1675, males
G 132 (61) 53 (46) 99 (51)
A 86 (39) 62 (54) 94 (49) 0.027
A1818T, males
A 149 (68) 95 (83) 143 (74)
T 71 (32) 20 (17) 50 (26) 0.013
Haplotypes, males
GT 71 (45) 19 (24) 50 (35)
AA 86 (55) 61 (76) 94 (65) 0.004
G1675A, females
G 113 (54) 219 (54) 144 (55)
A 97 (46) 185 (46) 120 (45) NS
A1818T, females
A 155 (74) 295 (73) 186 (70)
T 55 (26) 109 (27) 78 (30) NS
Haplotypes, females
GT 53 (36) 97 (36) 93 (40)
AA 94 (64) 169 (64) 141 (60) NS
GFR, glomerular filtration rate; NS, not significant.
Data are n (%). All end-stage renal disease patients were classified as
GFRo60 ml min1 1.73 m2.
adf=2.
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The FinnDiane database of more than 4000 patients with
type I diabetes (n¼ 4069) includes significantly more males
with DN (59 vs 41%) and end-stage renal disease (61 vs 39%)
than females (Po0.0001: unpublished observation). The
basis of this phenomenon remains to be established. As no
effect appeared in females, we hypothesize that the
X-chromosomal location of the AT2 gene specifically exposes
males with the 1675A genotype or AA haplotype to impaired
renal function, perhaps owing to the fact that males have only
a single set of alleles or haplotype.
The AT2 receptor plays an important role in the
developing kidney. The AT2-null mouse exhibits a variety
of urological abnormalities, and some studies have demon-
strated an association between polymorphisms of the AT2
gene and vesicouretic reflux,10 another renal disorder with a
male preponderance. Recently, it has become clear that
following injury to the diabetic kidney, many important
developmental genes are expressed, possibly acting in repair
and regeneration.11 Among these, AT2 is thought to play a
key role being linked to inhibition of cell growth, to
apoptosis, and to modulation of inflammation and matrix
protein accumulation in the kidney. In experimental DN,
blockade of the AT2 receptor prevents pathogenic changes in
the retina and the kidney.12,13 It is conceivable that
polymorphisms of the AT2 gene may have a similar
modulatory effect in type I diabetes. However, regarding
cardiovascular remodeling, recent data have also questioned
the role of AT2 receptor as having an effect opposite to that
of the deleterious AT1, as reviewed by Levy.5 It is thus
controversial whether the AT2 induces arterial hypertrophy
and fibrosis, or whether it has an inhibitory effect or both.
The renin–angiotensin–aldosterone system also plays an
important role in the control of blood pressure, a key risk
factor for progressive renal disease in diabetes. We have
recently shown that PP increases approximately 20 years
earlier in type I diabetic subjects than in non-diabetic
subjects.14 This is thought to reflect premature aging of the
arterial tree, whereas duration of diabetes appears to be a
strong determinant of premature increase in PP. A small
case–control study in non-diabetic subjects has shown an
association between polymorphisms in the AT2 gene and
prevalence of hypertension only for males.15 Furthermore,
the A allele of the A1675G has been associated specifically
with a more pronounced left ventricular hypertrophy, still
only in males.8,9 As the patients in these studies were non-
diabetic, they were perhaps too young to display any
detectable effect of the AT2 gene on PP. It is thus also
possible that the polymorphism can influence the mechan-
isms leading to left ventricular hypertrophy and left
ventricular overload, which could be detected by an elevated
PP in our study. The G1675A allele was independently
associated with PP in men after adjustment for standard risk
factors, although the absolute prevalence of hypertension did
not differ significantly between genotypes or haplotypes. This
may in part be explained by its association with renal
impairment. However, recent studies suggest that the impact
of AT2 polymorphisms may be greatest in those patients
with hypertension: In one study of non-diabetic men, the
AT2 1675A allele was associated with excess risk among those
with systolic hypertension, but coronary heart disease
risk was independent of AT2 genotype among those
normotensive.16
The fact that AT2 alleles were also associated with the
effective glucose disposal rate, a surrogate measure of insulin
sensitivity in patients with type I diabetes, was probably
driven by the blood pressure indices included in the
estimated glucose disposal rate formula, as glycosylated
hemoglobin and waist-to-hip ratio did not significantly differ
between haplotypes. Nonetheless, a direct effect cannot be
discounted, because activation of the AT2 receptor does
Table 3 | Overall clinical characteristics between males and females and between the GT and AA haplotypes of the AT2 gene in
each sex
Males Females Males Females
Variable All All P GT AA P GT AA P
n (%) 538 (54.0) 458 (46.0) — 142 (36.5) 247 (63.5) — 251 (37.9) 412 (62.1) —
Age (years) 41.6710.0 39.5710.0 0.001 40.279.8 42.6710.2 0.024 40.0710.0 39.579.8 NS
Duration of diabetes (years) 28.178.7 27.678.2 NS 26.878.1 28.578.7 NS 27.778.3 27.577.8 NS
HbA1c (%) 8.671.4 8.471.5 0.009 8.671.4 8.771.4 NS 8.471.4 8.471.5 NS
eGDR (mg kg1 min1) 4.8372.25 6.9572.48 o0.001a 5.2072.25 4.5072.20 0.004a 6.6672.55 7.0272.47 NS
SBP (mm Hg) 143719 138720 o0.001a 142717 145720 NS 138719 138722 NS
DBP (mm Hg) 83710 80710 o0.001a 85711 83710 NS 79710 80710 NS
PP (mm Hg) 60718 58717 NS 57715 62718 0.002a 58717 58719 NS
UAER (mg 24 h1)b 77 (1–7565) 207(1–6069) o0.001 68 (4–7565) 132 (1–5589) NS 167(1–4325) 19 (1–5259) NS
GFR (ml min1 1.73 m2)b 87.3732.4 76.1724.0 o0.001a 93.8732.9 83.4732.1 0.008c 74.7724.6 76.6724.2 NS
Diagnosed CHD 57 (11) 28 (6) 0.009d 9 (7) 34 (14) 0.022d 17 (7) 23 (6) NS
Retinal laser treatment 360 (68) 255 (56) o0.001 91 (65) 163 (67) NS 133 (54) 232 (57) NS
AT2, angiotensin II type 2 receptor; CHD, coronary heart disease; DBP, diastolic blood pressure; eGDR, estimated glucose disposal rate; GFR, glomerular filtration rate; HbA1c,
glycosylated hemoglobin; NS, not significant; PP, pulse pressure; SBP, systolic blood pressure; UAER, urinary albumin excretion rate.
Data are mean7s.d., median (range) or n (%).
aPo0.05 when adjusted for age.
bPatients with end-stage renal disease excluded.
cP=0.009 when adjusted for duration of diabetes, urinary albumin excretion rate, and use of angiotensin-converting enzyme inhibitors.
dP=NS when adjusted for age.
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inhibit insulin-induced extracellular signal-regulated protein
kinase-2 activity via a G-protein-mediated pathway.17
Data are convincing in support of the functionality of the
G1675A polymorphism. First, the G1675A involves a lariat
branchpoint motif in intron 1 where the A allele causes a
diminished splice efficiency and loss of receptor function.18
Secondly, the region is adjacent to an intron fragment
responsible for directing the gene transcription when the 50
flanking region of the gene is absent.19 Interestingly, a
genome-wide scan in a Finnish population with premature
coronary heart disease has pinpointed the locus containing
the AT2 gene.20
Although the AA haplotype of the AT2 gene was associated
with a higher PP and renal impairment, no independent
association, somewhat surprisingly, was seen with urinary
albumin excretion rate. However, not all patients with
microalbuminuria will develop overt nephropathy.21 Me-
chanistically, it is possible that functional polymorphisms in
the AT2 gene are more important in progression of renal
impairment (i.e., response to injury) than its initial
development. This is consistent with family studies suggest-
ing that the genetic predisposition to DN is not specific to
diabetes, but is more a risk for progressive renal disease in
general.
In conclusion, these data suggest a gender-dependent
association between the AT2 gene and progressive renal
disease and premature aging of the arterial tree in male
patients with type I diabetes, although these results require
further testing and confirmation in other populations and in
prospective studies.
MATERIALS AND METHODS
All type I diabetic patients who were classifiable according to their
urinary albumin excretion rate and who had been entered into the
database of the FinnDiane study by August 1999 participated in the
study. Consequently, this case–control, cross-sectional, nationwide
multicenter study involved 996 patients comprising their ascertained
renal status from 20 referral centers between 1994 and 1999.
Detailed clinical data and the classification procedure of the patients
into four groups according to urinary albumin excretion rate have
been described.22 The year of renal replacement therapy, year of
initiation of microalbuminuria, and year of DN came from medical
records. Prevalence of retinopathy, laser treatment, diabetes
diagnosis, antihypertensive medication, and diagnosed coronary
heart disease were also obtained from medical records. Informed
consent was obtained from all subjects participating in the study; the
study protocol followed the Declaration of Helsinki Principles and
was approved by all local ethics committees. Systolic and diastolic
clinically tested office blood pressure, registered as Korotkoff I and V
sounds, was measured in each center with a calibrated mercury
sphygmomanometer. Two measurements were performed, each after
at least 10 min of rest. PP was calculated as the systolic minus the
diastolic value. The serum and urine creatinine levels, estimated
glucose disposal rate, urinary albumin concentration, and glycosy-
lated hemoglobin were analyzed as described previously.22 GFR was
calculated with the Cockcroft–Gault formula.23 Impaired renal
function was defined as a creatinine clearance of less than
90 ml min1 1.73 m2 according to NKF K/DOQI guidelines.24
The genotypes of the polymorphisms in this study were
determined from DNA samples extracted from peripherally drawn
blood samples. Genotyping was performed by standard polymerase
chain reaction and a solid-phase minisequencing method. The
polymerase chain reaction primers of the G1675A and the A1818T
polymorphisms have been described elsewhere.25 For these poly-
morphisms, the minisequencing primers were 50-CTGTATTTTGC
AAAACTCCT-30 and 50-TTATGTTAATTTGTTAGGTC-30, respec-
tively. Genotyping of the G1675A polymorphism failed in two
patients owing to polymerase chain reaction failure. Linkage
disequilibrium was analyzed with the Linkage Disequilibrium
Analyzer 1.026 and the haplotypes were determined by PHASE
version 2.0.1.18 Males and females were analyzed separately in all
analyses.
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